Last reviewed · How we verify
Clotrimazole Troche
Clotrimazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting membrane integrity and causing fungal cell death.
Clotrimazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting membrane integrity and causing fungal cell death. Used for Oropharyngeal candidiasis (oral thrush).
At a glance
| Generic name | Clotrimazole Troche |
|---|---|
| Also known as | Mycelex |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Azole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Clotrimazole is an azole antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi. This blocks the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol precursors leads to increased membrane permeability and fungal cell lysis.
Approved indications
- Oropharyngeal candidiasis (oral thrush)
Common side effects
- Oral irritation or burning
- Nausea
- Unpleasant taste
- Gastrointestinal upset
Key clinical trials
- Use of Maqui Berry Extract in Treating Oral Candidiasis in Diabetes Mellitus Patients and Systemically Healthy Persons (PHASE4)
- Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation (PHASE4)
- A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. (PHASE3)
- Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches (PHASE2)
- Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis (PHASE3)
- B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clotrimazole Troche CI brief — competitive landscape report
- Clotrimazole Troche updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI